{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:45:38Z","timestamp":1792442738708,"version":"4.5.0"},"reference-count":53,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Vogt\u2013Koyanagi\u2013Harada syndrome (VKH) is a rare granulomatous autoimmune disease characterised by a systemic immune response directed against melanocytes. This multisystem condition primarily affects organs that are rich in melanocytes, such as the eyes, inner ear, meninges and skin. VKH might be responsible for the development of chronic uveitis and permanent visual impairment, particularly in cases where a diagnosis is delayed and treatment is not administered in a timely manner. A key factor in its pathogenesis is the loss of immune tolerance to melanocytes, driven by a T-cell\u2013mediated immune response and genetic susceptibility, including the presence of HLA-DRB1*04 antigens. In recent years, immune checkpoint inhibitors (ICIs) have become the standard treatment in oncology, including non-small cell lung cancer and unresectable melanoma. However, it should be noted that their utilisation carries with it the potential for immune-related adverse events, including rare cases of VKH-like uveitis. The objective of this review is to outline the clinical features of VKH syndrome, examine current diagnostic and treatment approaches, and emphasise the immunopathological mechanisms associated with drug-induced forms of VKH, with a particular focus on programmed cell death protein 1 (PD-1) inhibitors. The article also includes an analysis of the genetic, epigenetic, and environmental factors that predispose individuals to the disease. This analysis facilitates a deeper understanding of the pathogenesis of the disease and assists in the identification of patients at increased risk of drug-induced VKH manifestations.<\/jats:p>","DOI":"10.3390\/jcm15093490","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:12:09Z","timestamp":1777857129000},"page":"3490","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vogt\u2013Koyanagi\u2013Harada Syndrome: Clinical Features, Immunogenetic Predisposition and PD-1 Inhibitor-Induced Forms\u2014A Comprehensive Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2785-4985","authenticated-orcid":false,"given":"Sara Ma\u0142gorzata","family":"Or\u0142owska","sequence":"first","affiliation":[{"name":"Department of Health Sciences and Physical Culture, Student Scientific Association of Otolaryngology and Laryngological Oncology, Student Scientific Association \u201cFarMedLab\u201d, Radom University, Chrobrego 27, 26-600 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9211-6264","authenticated-orcid":false,"given":"\u0141ukasz","family":"Bednarczyk","sequence":"additional","affiliation":[{"name":"Department of Health Sciences and Physical Culture, Student Scientific Association of Otolaryngology and Laryngological Oncology, Student Scientific Association \u201cFarMedLab\u201d, Radom University, Chrobrego 27, 26-600 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Morshed","sequence":"additional","affiliation":[{"name":"Clinical Department of Otolaryngology and Laryngological Oncology, Mazovian Specialist Hospital in Radom, Radom University, 5 Aleksandrowicza Street, 26-617 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Tyniec","sequence":"additional","affiliation":[{"name":"Clinical Department of Otolaryngology and Laryngological Oncology, Mazovian Specialist Hospital in Radom, Radom University, 5 Aleksandrowicza Street, 26-617 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-9587","authenticated-orcid":false,"given":"Pawe\u0142","family":"Olczyk","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences and Health Sciences, Radom University, Chrobrego 27, 26-600 Radom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1159\/000541133","article-title":"Vogt-Koyanagi-Harada-like uveitis secondary to pembrolizumab in metastatic gastric cancer: A case report and review of the literature","volume":"17","author":"Denu","year":"2024","journal-title":"Case Rep. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","article-title":"Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma","volume":"40","author":"Bricout","year":"2017","journal-title":"J. Immunother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e062126","DOI":"10.1136\/bmjopen-2022-062126","article-title":"Criteria to define rare diseases and orphan drugs: A systematic review protocol","volume":"12","author":"Abozaid","year":"2022","journal-title":"BMJ Open"},{"key":"ref_4","unstructured":"Stern, E.M., and Nataneli, N. (2026, April 01). Vogt-Koyanagi-Harada syndrome, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574571\/."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wang, Y., Chen, Y., Zhou, H., Hong, Q., Yu, X., Ng, T.K., and Cen, L.-P. (2023). Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in southern China. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-02952-y"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Goyal, A., Shah, V., Anantharaman, G., and Gopalakrishnan, M. (2024). Vogt-Koyanagi-Harada disease: Current diagnosis and management. Advances in Ophthalmology, IntechOpen.","DOI":"10.5772\/intechopen.111594"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/IAE.0b013e3181c96a87","article-title":"Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India","volume":"30","author":"Martin","year":"2010","journal-title":"Retina"},{"key":"ref_8","first-page":"275","article-title":"Beyond the usual suspects: Unilateral optic disc edema as a rare initial sign of Vogt\u2013Koyanagi\u2013Harada syndrome","volume":"69","author":"Rana","year":"2025","journal-title":"Rom. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12348-025-00498-2","article-title":"Retrospective analysis of Vogt-Koyanagi-Harada\u2019s recurrence within a case series of nineteen patients followed between 2003 and 2018 in an academic center","volume":"15","author":"Kozyreff","year":"2025","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000496384","article-title":"Neurosarcoidosis occurring 6 years after onset of Vogt-Koyanagi-Harada disease","volume":"10","author":"Sehara","year":"2019","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12348-025-00484-8","article-title":"Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review","volume":"15","author":"Zhang","year":"2025","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.jtho.2018.04.026","article-title":"Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small cell lung cancer","volume":"13","author":"Tamura","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.autrev.2014.01.023","article-title":"Diagnosis and classification of Vogt-Koyanagi-Harada disease","volume":"13","author":"Sakata","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_14","first-page":"4","article-title":"Vogt-Koyanagi-Harada syndrome\u2014case report and analysis of contemporary views of diagnostic and therapeutic process","volume":"2","year":"2013","journal-title":"e-Pol. J. Vet. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment","volume":"52","author":"Du","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12348-014-0020-1","article-title":"Influence of molecular genetics in Vogt-Koyanagi-Harada disease","volume":"4","author":"Ng","year":"2014","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41423-023-01088-9","article-title":"A de novo missense mutation in MPP2 confers an increased risk of Vogt-Koyanagi-Harada disease as shown by trio-based whole-exome sequencing","volume":"20","author":"Liu","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_18","first-page":"153","article-title":"A comprehensive overview of uveitis: An association between Vogt-Koyanagi-Harada disorder and Beh\u00e7et\u2019s disease","volume":"11","author":"Bhattacharjee","year":"2024","journal-title":"Int. J. Ophthalmol. Clin. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ophtha.2014.09.025","article-title":"Genetic variations of IL17F and IL23A show associations with Beh\u00e7et\u2019s disease and Vogt-Koyanagi-Harada syndrome","volume":"122","author":"Hou","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000143","article-title":"Pembrolizumab-triggered uveitis: An additional surrogate marker for responders in melanoma immunotherapy?","volume":"39","author":"Diem","year":"2016","journal-title":"J. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ng.3061","article-title":"Genome-wide association analysis of Vogt-Koyanagi-Harada syndrome identifies two new susceptibility loci at 1p31.2 and 10q21.3","volume":"46","author":"Hou","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/19490976.2019.1700754","article-title":"Alterations of gut microbiota in Vogt-Koyanagi-Harada syndrome and their potential role in disease pathogenesis","volume":"11","author":"Ye","year":"2020","journal-title":"Gut Microbes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"146222","DOI":"10.1016\/j.gene.2022.146222","article-title":"The emerging role of epigenetics and gut microbiota in Vogt-Koyanagi-Harada syndrome","volume":"818","author":"Li","year":"2022","journal-title":"Gene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109553","DOI":"10.1016\/j.exer.2023.109553","article-title":"Epigenome-wide association study identifies Vogt-Koyanagi-Harada disease-associated DNA methylation loci in Chinese","volume":"233","author":"Su","year":"2023","journal-title":"Exp. Eye Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zou, Y., Li, J.J., Xue, W., Kong, X., Duan, H., Li, Y., and Wei, L. (2021). Epigenetic modifications and therapy in uveitis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.758240"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1074\/jbc.R116.761577","article-title":"Chemical signaling between gut microbiota and host chromatin: What is your gut really saying?","volume":"292","author":"Krautkramer","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_27","first-page":"511","article-title":"Zesp\u00f3\u0142 Vogta-Koyanagi-Harady u 11-letniej dziewczynki","volume":"107","year":"2005","journal-title":"Klin. Ocz."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09273948.2024.2331401","article-title":"Vogt-Koyanagi-Harada disease","volume":"32","author":"Smit","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9503795","DOI":"10.1155\/2020\/9503795","article-title":"The application of enhanced depth imaging spectral-domain optical coherence tomography in macular diseases","volume":"2020","author":"Wang","year":"2020","journal-title":"J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-022-00293-3","article-title":"Vogt-Koyanagi-Harada disease: The step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management","volume":"12","author":"Urzua","year":"2022","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kal, M., Brzd\u0119k, M., Tracz, J., Szadkowski, P., and Zar\u0119bska-Michaluk, D. (2025). Swept-source optical coherence tomography in the diagnosis and monitoring of optic nerve neuropathy in patients with Wernicke\u2019s encephalopathy due to hyperemesis gravidarum. J. Clin. Med., 14.","DOI":"10.3390\/jcm14113849"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4103\/ijo.IJO_1944_21","article-title":"Role of swept-source optical coherence tomography in management of acute Vogt-Koyanagi-Harada\u2019s disease","volume":"70","author":"Ganesh","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Qian, Y., Yang, J., Liang, A., Zhao, C., Gao, F., and Zhang, M. (2021). Widefield swept-source optical coherence tomography angiography assessment of choroidal changes in Vogt-Koyanagi-Harada disease. Front. Med., 8.","DOI":"10.3389\/fmed.2021.698644"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/IIO.0b013e3182662ee9","article-title":"Use of fundus autofluorescence in the diagnosis and management of uveitis","volume":"52","author":"Meleth","year":"2012","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kayaba\u015f\u0131, M. (2025). Clinical features and treatment options of Vogt-Koyanagi-Harada disease. Uveitis in the Clinic-Current Approaches and Future Directions in Diagnosis, Treatment, and Patient Care, IntechOpen.","DOI":"10.5772\/intechopen.1010862"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5114\/ko.2020.97501","article-title":"Vogt-Koyanagi-Harada disease\u2014A rare entity in the Polish population\u2014A case report","volume":"122","author":"Kaczmarek","year":"2020","journal-title":"Klin. Ocz."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K.A., Farooqi, H., and Aspatwar, A. (2023). PD-1 and PD-L1: Architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1296341"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cui, J.W., Li, Y., Yang, Y., Yang, H.K., Dong, J.M., Xiao, Z.H., He, X., Guo, J.H., Wang, R.Q., and Dai, B. (2024). Tumor immunotherapy resistance: Revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape. Biomedicines, 171.","DOI":"10.1016\/j.biopha.2024.116203"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Morch\u00f3n Araujo, D., Catani, G., Mirallas, O., Pretelli, G., S\u00e1nchez-P\u00e9rez, V., Vieito, M., Brana, I., Pujol Borrell, R., Garralda, E., and Hernando-Calvo, A. (2025). Emerging immunotherapy targets in early drug development. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115394"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"H751","DOI":"10.1152\/ajpheart.00378.2023","article-title":"Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications","volume":"325","author":"Banerjee","year":"2023","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhao, R.J., and Fan, X.X. (2025). Advances in antibody-based immune-stimulating drugs: Driving innovation in cancer therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041440"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"C1475","DOI":"10.1152\/ajpcell.00189.2022","article-title":"Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis","volume":"323","author":"Crump","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wang, J.-N., Zhang, Y., Huang, C.-Y., Li, K., and Yu, X.-B. (2024). Development of Vogt\u2013Koyanagi\u2013Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: A case report. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03484-9"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1080\/09273948.2021.1884889","article-title":"Development of Vogt\u2013Koyanagi\u2013Harada disease-like uveitis during treatment by anti-programmed death ligand-1 antibody for non-small cell lung cancer: A case report","volume":"30","author":"Suwa","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000496682","article-title":"Vogt\u2013Koyanagi\u2013Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma","volume":"10","author":"Obata","year":"2019","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kikuchi, R., Kawagoe, T., and Hotta, K. (2020). Vogt\u2013Koyanagi\u2013Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: A case report. BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-01519-5"},{"key":"ref_51","first-page":"9565205","article-title":"Outcome of nivolumab-induced Vogt\u2013Koyanagi\u2013Harada disease-like uveitis in a patient managed without intravenous methylprednisolone therapy","volume":"2023","author":"Nagai","year":"2023","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"ref_52","first-page":"77","article-title":"Vogt\u2013Koyanagi\u2013Harada-like syndrome in a patient treated with pembrolizumab for metastatic colorectal cancer","volume":"40","author":"Kontou","year":"2025","journal-title":"Acta Ophthalmol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"23247096251355151","DOI":"10.1177\/23247096251355151","article-title":"Cemiplimab-induced Vogt\u2013Koyanagi\u2013Harada-like syndrome in a patient with cutaneous squamous cell carcinoma of the lower back","volume":"13","author":"Nidha","year":"2025","journal-title":"J. Investig. Med. High. Impact Case Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3490\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:32:09Z","timestamp":1777858329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093490"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093490","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]}}}